CM 101 - ChemomAb

Drug Profile

CM 101 - ChemomAb

Alternative Names: CM-101 - ChemomAb

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemomAb
  • Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Chemokine CCL24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic scleroderma
  • Preclinical Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis

Most Recent Events

  • 23 Nov 2017 Preclinical development in Idiopathic pulmonary fibrosis and primary sclerosing cholangitis is still underway in Israel
  • 20 Oct 2017 Pharmacodynamic data from preclinical trials in Non-alcoholic steatohepatitis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 30 Jul 2017 Phase-I clinical trials in Systemic scleroderma (In volunteers) in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top